Evidence map›Paper›PMID 37903943›Full record

ArticleDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2024

Cost minimization analysis of subcutaneous trastuzumab versus intravenous biosimilar trastuzumab: policy recommendations for breast cancer treatment in Malaysia.

Jin Ee Heng, Sivaraj Raman, Zhi Yen Wong, Valerine Jen Nin Beh

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Jin Ee HengPharmacy Department, Penang General Hospital, Ministry of Health Malaysia, Penang, Malaysia. joelheng7890@gmail.com.ORCID http://orcid.org/0009-0002-5446-7055
Sivaraj RamanCentre for Health Economics Research, Institute for Health Systems Research, National Institutes of Health, Shah Alam, Malaysia.
Zhi Yen WongPharmacy Department, Penang General Hospital, Ministry of Health Malaysia, Penang, Malaysia.
Valerine Jen Nin BehPharmacy Department, Penang General Hospital, Ministry of Health Malaysia, Penang, Malaysia.
Ministry of Health · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCurrent clinical practice recommends switching innovator intravenous trastuzumab (IV-TZM

methodsThis activity-based costing study consists of (1) a retrospective medical record abstraction to determine patient details to estimate drug costs and (2) a time-motion study to quantify personnel time, patient time, and consumables used. The total cost of both SC-TZM and IV-TZM

resultsThe mean total cost of SC-TZM and IV-TZM

conclusionThe study evidenced that IV-TZM

Indexed as

Biosimilar PharmaceuticalsBreast NeoplasmsDrug CostsTrastuzumabAdministration, IntravenousAntineoplastic Agents, ImmunologicalFemaleHumansInjections, SubcutaneousMalaysiaMiddle AgedRetrospective StudiesAntineoplastic Agents, ImmunologicalBiosimilar PharmaceuticalsTrastuzumabBiosimilarClinical practiceCostPublic healthcareTrastuzumab

Identifiers

PMID37903943
PMCPMC11087381
OpenAlexW4388033124

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.